Canexis Pharma has received an extended GMP manufacturing license (Part I) from Swissmedic for the production of bulk finished medicinal products. This means that Canexis is now able to produce not only active ingredients such as...
A day of knowledge and development: Our annual internal GMP training day 2024 To support our continuous efforts to ensure the highest quality standards…
Canexis Pharma AG is expanding at its location in Schlattingen. With the acquisition of another 2 plots and around 2000m2 of building land, the company is ideally positioned for the continuous expansion of the P...
Canexis Pharma AG is present at Cannabis Europa 2024 in London! This is one of the leading trade fairs for medical cannabis in Europe, known for its networking activities, interesting pan...
In addition to the GMP approval, Canexis Pharma AG has also acquired the narcotics (BTM) operating license to handle controlled substances. This enables the purchase, processing…
Canexis Pharma AG (“Canexis”), an up-and-coming Swiss company in the field of pharmaceutical cannabis products, has received the manufacturing and narcotics license for cannabis products from Swissmedic…
Canexis Pharma AG is pleased to announce that it has received a high-profile delegation from Thailand. The visit marks a significant meeting between the young company…
Canexis Pharma AG has developed a modern hygiene concept. It is based on a detailed zone plan and extends over three floors for integrated process chains for the production of C…
Canexis Pharma AG is setting new standards with its completed interior construction. The planning of the building focused not only on a maximum solution, but also on a lean production infrastructure…
With the new electric steam generator from the JUMAG EDI series, Canexis Pharma AG achieves an output of 120 kW and at the same time has a space-saving and low-maintenance steam generator. That's how it goes…